Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Operating Leases (2019 - 2025)

Amicus Therapeutics' Operating Leases history spans 7 years, with the latest figure at $41.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 23.48% year-over-year to $41.0 million, compared with a TTM value of $41.0 million through Dec 2025, down 23.48%, and an annual FY2025 reading of $41.0 million, down 23.48% over the prior year.
  • Operating Leases for Q4 2025 was $41.0 million at Amicus Therapeutics, down from $42.2 million in the prior quarter.
  • The five-year high for Operating Leases was $53.5 million in Q4 2024, with the low at $41.0 million in Q4 2025.
  • Average Operating Leases over 5 years is $47.6 million, with a median of $47.4 million recorded in 2024.
  • Year-over-year, Operating Leases grew 19.58% in 2022 and then decreased 23.48% in 2025.
  • Tracing FOLD's Operating Leases over 5 years: stood at $43.4 million in 2021, then grew by 18.94% to $51.6 million in 2022, then fell by 5.24% to $48.9 million in 2023, then rose by 9.53% to $53.5 million in 2024, then decreased by 23.48% to $41.0 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Operating Leases are $41.0 million (Q4 2025), $42.2 million (Q3 2025), and $43.4 million (Q2 2025).